← Back to Screener
Dyne Therapeutics, Inc. Common Stock (DYN)
Price$20.02
Favorite Metrics
Price vs S&P 500 (26W)36.52%
Price vs S&P 500 (4W)6.74%
Market Capitalization$3.37B
All Metrics
Book Value / Share (Quarterly)$5.89
P/TBV (Annual)2.69x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.57
Price vs S&P 500 (YTD)0.21%
EPS (TTM)$-3.54
10-Day Avg Trading Volume1.77M
EPS Excl Extra (TTM)$-3.54
EPS (Annual)$-3.47
ROI (Annual)-39.80%
Cash / Share (Quarterly)$6.73
ROA (Last FY)-37.59%
EBITD / Share (TTM)$-3.64
ROE (5Y Avg)-92.38%
Cash Flow / Share (Annual)$-2.57
P/B Ratio3.46x
P/B Ratio (Quarterly)3.26x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-173.82x
ROA (TTM)-50.94%
EPS Incl Extra (Annual)$-3.47
Current Ratio (Annual)22.25x
Quick Ratio (Quarterly)21.94x
3-Month Avg Trading Volume2.39M
52-Week Price Return160.66%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.48
52-Week High$25.00
EPS Excl Extra (Annual)$-3.47
CapEx CAGR (5Y)77.97%
26-Week Price Return45.27%
Quick Ratio (Annual)21.94x
13-Week Price Return16.96%
Total Debt / Equity (Annual)0.15x
Current Ratio (Quarterly)22.25x
Enterprise Value$2,623.756
Book Value / Share Growth (5Y)-4.93%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.73
3-Month Return Std Dev70.95%
Net Income / Employee (TTM)$-2
ROE (Last FY)-45.90%
EPS Basic Excl Extra (Annual)$-3.47
Total Debt / Equity (Quarterly)0.15x
EPS Incl Extra (TTM)$-3.54
ROI (TTM)-54.90%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.54
Price vs S&P 500 (52W)125.57%
Year-to-Date Return4.35%
5-Day Price Return7.42%
EPS Normalized (Annual)$-3.47
ROA (5Y Avg)-63.28%
Month-to-Date Return12.58%
Cash Flow / Share (TTM)$-3.59
EBITD / Share (Annual)$-3.64
LT Debt / Equity (Annual)0.15x
ROI (5Y Avg)-91.16%
LT Debt / Equity (Quarterly)0.15x
EPS Basic Excl Extra (TTM)$-3.54
P/TBV (Quarterly)4.46x
P/B Ratio (Annual)3.26x
Book Value / Share (Annual)$5.89
Price vs S&P 500 (13W)14.10%
Beta1.24x
Revenue / Share (TTM)$0.00
ROE (TTM)-61.45%
52-Week Low$7.38
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DYNDyne Therapeutics, Inc. Common Stock | — | — | — | — | $20.02 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Dyne Therapeutics is a clinical-stage biopharmaceutical company developing treatments for genetically driven neuromuscular diseases. Its proprietary FORCE platform addresses a critical delivery challenge to muscle tissue and the central nervous system that limits existing therapies. The company has multiple programs in clinical development targeting distinct neuromuscular indications.